Cargando…

Proprotein convertase 1/3 inhibited macrophages: A novel therapeutic based on drone macrophages

We demonstrated here thanks to proteomic, that proprotein convertase 1/3 knockdown macrophages present all the characteristic of activated pro-inflammatory macrophages. TLR4 and TLR9 signaling pathways can be enhanced leading to the secretion of pro-inflammatory factors and antitumor factors. We can...

Descripción completa

Detalles Bibliográficos
Autores principales: Duhamel, Marie, Rodet, Franck, Murgoci, Adriana, Wisztorski, Maxence, Day, Robert, Fournier, Isabelle, Salzet, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988551/
https://www.ncbi.nlm.nih.gov/pubmed/29900108
http://dx.doi.org/10.1016/j.euprot.2016.03.003
Descripción
Sumario:We demonstrated here thanks to proteomic, that proprotein convertase 1/3 knockdown macrophages present all the characteristic of activated pro-inflammatory macrophages. TLR4 and TLR9 signaling pathways can be enhanced leading to the secretion of pro-inflammatory factors and antitumor factors. We can control their activation by controlling one enzyme, PC1/3. In a tumor context, PC1/3 inhibition in macrophages may reactivate them and lead to a cytokine storm after stimulation “at distance” with a TLR ligand. Therefore, we name these proprotein convertase inhibited macrophages the “drone macrophages”. They constitute an innovative cell therapy to treat efficiently tumors.